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ABSTRACT 
Novel drug delivery systems (NDDS) are the key area of pharmaceutical research and Development. The reason is relatively low 
development cost and time required for introducing a NDDS as compared to new chemical entity. Many conventional drug delivery 
systems have been designed to modulate the release a drug over an extended period of a time. Various designs are available to 
control or modulate the drug release from a dosage forms. Majority of oral CR dosage forms fall in the category of matrix, reservoir 
or osmotic systems. Osmotically controlled drug delivery systems (OCDDS) is one of the most promising drug delivery technology 
that use osmotic pressure as a driving force for controlled delivery of active agents. Drug release from OCDDS is independent of pH 
and hydrodynamic conditions of the body because of the semipermeable nature of the Rate controlling membrane and the design of 
deliver orifice used in osmotic systems, so a high degree of In vitro/In vivo correlation is achieved. Osmotic drug delivery systems 
release the drug with the zero order kinetics which does not depend on the initial concentration and the physiological factors of GIT. 
This review brings out new technologies, fabrication and recent clinical research in osmotic drug delivery. 
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INTRODUCTION 
Novel drug delivery systems (NDDS) are the key area of 
pharmaceutical research and Development. The reason is 
relatively low development cost and time required for 
introducing a NDDS as compared to new chemical 
entity. Many conventional drug delivery systems have 
been designed to modulate the release a drug over an 
extended period of a time
1
. Various designs are available 
to control or modulate the drug release from a dosage 
forms. Majority of oral CR dosage forms fall in the 
category of matrix, reservoir or osmotic systems. 
Conventional matrix or reservoir type formulations 
exhibits problem of bioavailability fluctuations due to 
gastric pH variations. Moreover, the release of drugs 
from these systems is affected by the hydrodynamic 
conditions of the body. The rate and extent of drug 
absorption from conventional formulations may vary 
greatly depending on the factors such as physico-
chemical properties of the drug, presence of Excipients, 
physiological factors such as presence or absence of 
food, pH of the gastro-intestinal tract (GI) and so on
 2
. 
However, drug release from oral controlled release 
dosage forms may be affected by pH, GI motility and 
presence of food in the GI tract
3
. Osmotically controlled 
drug delivery systems (OCDDS) is one of the most 
promising drug delivery technology that use osmotic 
pressure as a driving force for controlled delivery of 
active agents. Drug release from OCDDS is independent 
of pH and hydrodynamic conditions of the body because 
of the semi permeable nature of the Rate-controlling 
membrane and the design of deliver orifice used in 
osmotic systems, so a high degree of In vitro/In vivo 
correlation is achieved.
4, 5
 
Osmosis can be defined as the net movement of water 
across a selectively permeable membrane driven by a 
difference in osmotic pressure across the membrane. It is 
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driven by a difference in solute concentrations across the 
membrane that allows passage of water, but rejects most 
solute molecules or ions. Osmotic pressure is the 
pressure which, if applied to the more concentrated 
solution, would prevent transport of water across the 
semi permeable membrane. Osmotic Pump Controlled 
Release Preparation is a novel drug delivery system with 
eternally drug delivery rate as characteristic and 
controlled with the osmotic pressure difference between 
inside and outside of the semipermeable membrane as 
drug delivery power 
6
.Recently, osmotic tablets have 
been developed in which the delivery orifice is formed 
by the incorporation of a leachable component in the 
coating. Once the tablet comes in contact with the 
aqueous environment, the water-soluble component 
dissolves, and an osmotic pumping system results. 
Subsequently, water diffuses into the core through the 
micro porous membrane, setting up an osmotic gradient 
and thereby controlling the release of drug. Osmosis can 
be defined as the spontaneous movement of a solvent 
from a solution of lower solute concentration to a 
solution of higher solute concentration through an ideal 
semipermeable membrane, which is permeable only to 
the solvent but impermeable to the solute. The pressure 
applied to the higher-concentration side to inhibit 
solvent flow is called the osmotic pressure. 
Advantages of Osmotic Drug Delivery System
7, 8
 
Apart from the general advantages of controlled drug 
delivery systems, osmotic pumps have 
Certain unique advantages, as follows: 
1. Delivery of drug from osmotic pumps can be designed 
to follow true zero-order kinetics. 
2. Delivery may be delayed or pulsed, if desired. 
3. Drug release from osmotic pumps is independent of 
the gastric pH and hydrodynamic 
Conditions of the body. 
4. Higher release rates are possible from osmotic 
systems than with conventional diffusion 
Based drug delivery systems. 
5. The delivery rate of drug(s) from these systems is 
highly predictable and programmable 
by modulating the release control parameters. 
6. A high degree of In vitro/In vivo correlation can be 
obtained from osmotic pumps. 
7. Drug release from the osmotic systems is minimally 
affected by the presence of food. 
 
Classification of Osmotic Pump Drug Delivery System 9 
Implantable     Oral osmotic Pump  Specific types   
The Rose and Nelson Pump 
  
Single chamber osmotic pump -
1.Elementary osmotic pump  
Controlled porosity osmotic pump,   
Higuchi Leeper Pump   Multi chamber osmotic pump:  
1.Push pull osmotic pump,  
2.Osmotic pump with non-
expanding second chamber  
Osmotic bursting osmotic pump 
Higuchi Theuwes pump  Liquid OROS,   
Delayed Delivery osmotic system 
OROS-CT (colon targeting),  
sandwiched oral therapeutic system 
Implantable Mini osmotic 
pump Osmotic pump for insoluble drugs,  
Monolithic osmotic system and OSMAT  
 
Key Milestones in OCDDS development 
Rose-Nelson Pump 
About 75 years after discovery of the osmosis principle, 
it was first used in the design of drug delivery 
systems.(Rose and Nelson 415) Rose and Nelson, the 
Australian scientists, were initiators of osmotic drug 
delivery. In 1955, they developed an implantable pump, 
which consisted of three chambers: a drug chamber, a 
salt chamber contains excess solid salt, and a water 
chamber. The drug and water chambers are separated by 
rigid semipermeable membrane. The difference in 
osmotic pressure across the membrane moves water 
from the water chamber into the salt chamber. The 
volume of the salt chamber increases because of this 
water flow, which distends the latex diaphragm 
separating the salt and drug chambers, thereby pumping 
drug out of the device. The design and mechanism of 
this pump is comparable to modern push-pull osmotic 
pump. The major disadvantage of this pump was the 
water chamber, which must be charged before use of the 
pump
 10 
 
Figure 1: Rose-Nelson Pump 
Several simplifications in Rose-Nelson pump were 
made by Alza Corporation in early 1970s. The Higuchi-
Leeper pump is modified version of Rose-Nelson pump. 
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It has no water chamber, and the device is activated by 
water imbibed from the surrounding environment. 
 
Figure 2: Higuchi-Leeper Pump 
The pump is activated when it is swallowed or 
implanted in the body. This pump consists of a rigid 
housing, and the semi permeable membrane is supported 
on a perforated frame. It has a salt chamber containing a 
fluid solution with excess solid salt. Recent modification 
in Higuchi-Leeper pump accommodated pulsatile drug 
delivery. The pulsatile release was achieved by the 
production of a critical pressure at which the delivery 
orifice opens and releases the drug.(Higuchi and Leeper 
; Higuchi and Leeper)
11
 
Higuchi-Theeuwes Pump 
In the early 1970s, Higuchi and Theeuwes developed 
another, even simpler variant of the Rose-Nelson pump. 
As with the Higuchi-Leeper pump, water to activate the 
osmotic action of the pump is obtained from the 
surrounding environment. In the Higuchi-Theeuwes 
device, however, the rigid housing is dispensed with and 
the membrane acts as the outer casing of the pump. This 
membrane is quite sturdy and is strong enough to 
withstand the pumping pressure developed inside the 
device. The device is loaded with the desired drug prior 
to use. When the device is placed in an aqueous 
environment, release of the drug follows a time course 
set by the salt used in the salt chamber and the 
permeability of the outer membrane casing. Most of the 
Higuchi-Theeuwes pumps use a dispersion of solid salt 
in a suitable carrier for the salt Chamber of the 
device.
12.13
 
  
Figure 3: Theeuwes miniature osmotic pump 
 
Implantable Mini osmotic pump 
Implantable Mini osmotic pump shown in figure 3 it is 
composed of three concentric layers-the drug reservoir, 
the osmotic sleeves and the rate controlling semi 
permeable membrane. The additional component called 
flow moderator is inserted into the body of the osmotic. 
The inner most compartment of drug reservoir which is 
surrounded by an osmotic sleeve, a cylinder containing 
high concentration of osmotic agent. The osmotic sleeve 
is covered by a semi permeable membrane when the 
system is placed in aqueous environment water enters 
the sleeve through semi permeable membrane, 
compresses the flexible drug reservoir and displaces the 
drug solution through the flow moderator. These pumps 
are available with variety of delivery rates between 0.25 
to 10ml per hour and delivery duration between one day 
and four weeks.
14 15
 
Single chamber osmotic pump: 
A. Elementary osmotic pump:-  
Elementary osmotic pump was invented by Theeuwes in 
1974 and it essentially contains an active agent having a 
suitable osmotic pressure, it is fabricated as a tablet 
coated with semi permeable membrane, usually cellulose 
acetate. 25 A small orifice is drilled through the 
membrane coating. (When this coated tablet is exposed 
to an aqueous environment, the osmotic pressure of the 
soluble drug inside the tablet draws water through the 
semi permeable coating and a saturated aqueous solution 
of drug is formed inside the device. The membrane is 
non-extensible and the increase in volume due to 
inhibition of water raises the hydrostatic pressure inside 
the tablet, eventually leading to flow of saturated 
solution of active agent out of the device through a small 
orifice. 
16, 17
 
 
Figure 4: Elementary Osmotic Pump 
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B. Push–Pull Osmotic Pump (PPOP) 
The two-layer push–pull osmotic tablet system appeared 
in 1980s. Push pull osmotic pump is a modified 
elementary osmotic pump through, which it is possible 
to deliver both poorly water-soluble and highly water 
soluble drugs at a constant rate. The push–pull osmotic 
tablet consists of two layers, one containing the drug and 
the other an osmotic agent and expandable agent. A 
semipermeable membrane that regulates water influx 
into both layers surrounds the system. While the push–
pull osmotic tablet operates successfully in delivering 
water-insoluble drugs, it has a disadvantage that the 
complicated laser drilling technology should be 
employed to drill the orifice next to the drug 
compartment
 18
. 
 
Figure 5: Push–Pull Osmotic Pump (PPOP) 
C. Osmotic Pump with Non Expanding Second 
Chamber 
The second category of multi-chamber devices 
comprises system containing a non-expanding second 
chamber. This group can be divided into two sub groups, 
depending on the function of second chamber. In one 
category of these devices, the second chamber is used to 
dilute the drug solution leaving the devices. This is 
useful because in some cases if the drug leaves the oral 
osmotic devices a saturated solution, irritation of GI tract 
is a risk. Example: The problem that leads to withdrawal 
of osmosin, the device consists of a normal drug 
containing porous tablet from which drug is released as a 
saturated solution. However before the drug can escape 
from the device it must pass through a second chamber. 
Water is also drawn osmotically into this chamber either 
because of osmotic pressure of drug solution or because 
the second chamber contain, water soluble diluents such 
as NaCl. This type of devices consist of two rigid 
chamber, the first chamber contains a biologically inert 
osmotic agent, such as sugar or a simple salt like sodium 
chloride, the second chamber contains the drug. In use 
water is drawn into both the chamber through the 
surrounding semi permeable membrane. The solution of 
osmotic agent formed in the first chamber then passes 
through the connecting hole to the drug chamber where 
it mixes with the drug solution before exiting through 
the micro porous membrane that form a part of wall 
surrounding the chamber. The device could be used to 
deliver relatively insoluble drugs
.19
 
 
Specific types 
Controlled Porosity Osmotic Pump 
A controlled porosity osmotic pump-based drug delivery 
system Unlike the elementary osmotic pump (EOP) 
which consists of an osmotic core with the drug 
surrounded by a semipermeable membrane drilled with a 
delivery orifice, controlled porosity of the membrane is 
accomplished by the use of different channeling agents 
in the coating. The CPOP contains water soluble 
additives in coating membrane, which after coming in 
contact with water; dissolve resulting in an in-situ 
formation of a microporous membrane. Then the 
resulting membrane is substantially permeable to both 
water and dissolved solutes and the mechanism of drug 
release from these systems was found to be primarily 
osmotic, with simple diffusion playing a minor role 
20, 21
. 
Drug delivery from asymmetric membrane capsule is 
principally controlled by the osmotic pressure of the 
core formation. In-situ formed delivery orifice in the 
asymmetric membrane in mainly responsible for the 
solubilization in the core for a drug with poor water 
solubility 
22.
 
 
Figure 6: Controlled Porosity Osmotic Pump 
Osmotic bursting osmotic pump 
This system is similar to an EOP expect delivery orifice 
is absent and size may be smaller. When it is placed in 
an aqueous environment, water is imbibed and hydraulic 
pressure is built up inside until the wall rupture and the 
content are released to the environment. Varying the 
thickness as well as the area the semi permeable 
membrane can control release of drug. This system is 
useful to provide pulsated release . Liquid OROS: 
Liquid OROS are designed to deliver drugs as liquid 
formulations and combine the benefits of extended 
release with high bioavailability. They are of three types: 
a) L OROS hard cap b) L OROS soft cap c) delayed 
liquid bolus delivery system.
23
 
Sandwiched Osmotic Tablets (SOTS) 
In this a tablet core composed of polymeric push layer 
sandwiched between two drug layers with two delivery 
orifices. When placed in the aqueous environment the 
middle push layer containing the swelling agent swells 
and the drug is released from the two orifices situated on 
opposite sides of the tablet and thus SOTS can be 
suitable for drugs prone to cause local irritation of the 
gastric mucosa. 
24
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Figure 7: Sandwiched osmotic tablets 
Osmotic pump for insoluble drugs: The device concerns 
an osmotic agent for dispensing beneficial active agent 
that has poor solubility in water. The core of the system 
comprises a beneficial amount of a substantially water- 
insoluble active agent, which is lipid soluble or lipid- 
wettable; a sufficient amount of water insoluble lipid 
carrier, which is liquid at the temperature of use to 
dissolve or suspend the drug and agent to ensure the 
release of the lipid carrier of the drug from the pump 
Basic Component of Osmotic System  
 Drug  
 Osmotic agent  
 Semipemiable membrane  
 Wicking agent  
 Pore forming  
Drug  
All drugs are not suitable for osmotic system as prolong 
action medication .Drugs those which has biological 
half-life more than 12 hr e.g.: Diazepam and drug which 
have very short half life i.e. less than 1 hr e.g. Penicillin 
G, furosemide are not suitable candidate for osmotic 
controlled release. Drug which have biological half-life 
in between 1 – 6 hrs and which is used for prolonged 
cure of diseases are ideal applicant for osmotic systems. 
25 
 
Drug having following characteristics are suitable for 
formulation  
1. It should have short half-life  
2. Prolonged release of drug should be desired.  
3. It should be potent in nature.  
4. Solubility of drug should not be very high or very 
low. 
26 
 
Osmotic agent  
These are also known as osmogens or osmogents and are 
used to create osmotic pressure inside the system. When 
the solubility of drug is low then the drug will show zero 
order release but at a slow rate. To enhance the release 
rate osmotic agent is added in the formulation. Osmotic 
agent creates a very high osmotic pressure gradient 
inside the system and increases release rate of drug.
 27
 
Some of the commercially used osmotic agents  
Sodium chloride, Fructose, sucrose, Potassium chloride, 
Xylitol, Sorbitol, citric acid, Dextrose, Manitole and 
Lactose. 
Semi permeable Membrane  
Since the membrane in osmotic systems is semi 
permeable in nature, any polymer that is permeable to 
water but impermeable to solute can be selected.13 
Cellulose acetate is a commonly employed semi 
permeable polymer for the preparation of osmotic 
pumps. It is available in different acetyl content grades. 
Particularly, acetyl content of 32% and 38% are widely 
used. Acetyl content is described by the degree of 
substitution (DS), i.e. the average number of hydroxyl 
groups on the anhydroglucose unit of the polymer 
replaced by substituting group. Some of the polymers 
that can be used for above purpose include cellulose 
esters such as cellulose acetate, cellulose diacetate, 
cellulose triacetate, cellulose propionate, cellulose 
acetate butyrate, and cellulose ethers like ethyl cellulose.  
The Semi Permeable Membrane must meet some 
performance criteria. 
 The material must possess sufficient wet strength (-
105) and wet modulus so as to retain its dimensional 
integrity during the operational lifetime of the 
device.  
 The membrane exhibit sufficient water permeability 
so as to retain water flux rate in the desired range. 
The water vapor transmission rates can be used to 
estimate water flux rates.  
 The reflection coefficient and leakiness of the 
osmotic agent should approach the limiting value of 
unity. Unfortunately, polymer membranes that are 
more permeable to water are also, in general more 
permeable to the osmotic agent.  
 The membrane should also be biocompatible.28,29 
Wicking agent  
The wicking agents are those agents which help to 
increase the contact surface area of the drug with the 
incoming aqueous fluid. The use of the wicking agent 
help to enhance the rate of drug released from the orifice 
of the drug. The examples are colloidal silicon dioxide, 
PVP & Sodium laryl sulphate. 
30
  
Pore Forming Agents  
The pore-forming agents cause the formation of micro 
porous membrane. The micro porous wall may be 
formed in situ by a pore-former by its leaching during 
the operation of the system. The pore-formers can be 
inorganic or organic and solid or liquid in nature. For 
example, alkaline metal salts such as sodium chloride, 
sodium bromide, potassium chloride, potassium 
sulphate, potassium phosphate etc., alkaline earth metals 
such as calcium chloride and calcium nitrate, 
carbohydrates such as sucrose, glucose, fructose, 
mannose, lactose, sorbitol, and mannitol and, diols and 
polyols such as poly hydric alcohols, polyethylene 
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glycols and polyvinyl pyrrolidone can be used as pore 
forming agents.
31
 
Coating solvents  
The primary function of solvent system is to dissolved or 
dispersed the polymer and other additive and convey 
them to substrate surface. solvent used to prepare 
polymeric solution include inert inorganic and organic 
solvents that do not adversely harm the core ,wall and 
other material .the various types of solvents and their 
combinations are as follows: Methylene chloride, 
methanol, isopropyl alcohol, dichloromethane , ethyl 
acetate, acetone, carbon tetrachloride, cyclohexane, 
butyl alcohol, water etc and the mixture of solvents such 
as acetone-methanol(80:20), methylene chloride- 
methanol (79:21), acetone-ethanol(80:20), methylene 
chloride-methanol-water (75:22:3) 
32  
Mechanism of drug release  
Tablet has rigid water permeable jacket with one or 
more laser dried small holes. As the tablet passes 
through the body the osmotic pressure of the tablet 
pushes the active drug through the opening in the tablet. 
The basic equation which applies to osmotic systems is  
dM/ dt= dV /dt.c ………(a) 
Where,  
dM /dt= mass release  
dV/dt = volumetric pumping rate  
c = concentration of drug But,  
dV / dt= (A/ h)Lp 
(σ ΔΠ-Δp)  
Where,  
A= membrane area, 
h= thickness of membrane, 
Lp= mechanical permeability, 
σ =reflection coefficient, 
ΔΠ=osmotic pressure difference, 
Δp = hydrostatic pressure difference  
As the size of orifice delivery increases. 
 Δp decrease, so ΔΠ >> Δp and equation becomes  
dV / dt = A/ h Lp(σ ΔΠ) 
When the osmotic pressure of the formulation is large 
compared to the osmotic pressure of the environment, p 
can be substituted for Dp.  
dV / dt= A / h Lp 
σΠ = A / hk Π 
(k = Lpσ = membrane permeability), Now, equation (a) 
can be given as  
dM / dt = (A / h) k Π c = (A / h) k Π S (S = solubility of 
drug, c taken as S) 
CONCLUSION 
In osmotic delivery systems, osmotic pressure provides 
the driving force for drug release. Increasing pressure 
inside the dosage form from water incursion causes the 
drug to release from the system. The major advantages 
include precise control of zero-order or other patterned 
release over an extended time period consistent release 
rates can be achieved irrespective of the environmental 
factors at the delivery site. However, a complex 
manufacturing process and higher cost compared with 
conventional dosage. Forms limit their use. Although not 
all drugs available for treating different diseases require 
such precise release rates, once-daily formulations based 
on osmotic principles are playing an increasingly 
important role in improving patient compliance. 
Therefore, most of the currently marketed products are 
based on drugs used in long-term therapies for diabetes, 
hypertension, attention-deficit disorder, and other 
chronic disease states. Besides oral osmotic delivery 
systems, implants that work on osmotic principles are 
promising for delivery of a wide variety of molecules 
with a precise rate over a long period of time. Further, 
with the discovery of newer and potent drugs by the 
biotechnology industry, the need to deliver such 
compounds at a precise rate certainly will pave the way 
for osmotic delivery systems to play an increasingly 
important role in drug delivery. 
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